The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

B Cell Lymphoma Clinical Trial

Official title:

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03101709
• Other study ID #: HenanCH109
• Status: Recruiting
• Phase: Phase 1
• First received: March 30, 2017
• Last updated: April 4, 2017
• Start date: August 2016
• Est. completion date: July 2019

Study information

• Verified date: March 2017
• Source: Henan Cancer Hospital
• Contact: Yongping Song
• Email: ph200811[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a clinical study to observe the safety and feasibility of chimeric antigen receptor 19 (CART-19) cells in relapsed and refractory patients with CD19+ B cell lymphoma.

Description:

This is a study for the patients with B cell lymphoma. Subjects will be staged and the suitability of their T cells for CART-19 manufacturing will be determined at entry phase. Subjects will be collected their T cells and modify them, the modification is a genetic change, that CD19:4-1BB:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects.

The purpose of this study is to assess ssess the safety and feasibility of CART-19 cells in the patients with relapsed and refractory CD19+ B cell lymphoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: July 2019
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. 18 years to 70 years, expected survival > 3 months;

2. CD19 positive B-cell lymphoma;

3. KPS >80;

4. Having at least one measurable lesions;

5. Cardiac function: 1-2 levels; Liver: TBIL=3ULN,AST =2.5ULN,ALT =2.5ULN; kidney:

Cr=1.25ULN; bone marrow: WBC = 3.0×109/L, Hb =90 g/L, PLT = 80×109/L);

6. No serious allergic constitution;

7. No other serous diseases that conflicts with the clinical program;

8. No other cancer history;

9. No serious mental disorder;

10. Informed consent is signed by a subject or his lineal relation.

Exclusion Criteria:

1. Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test);

2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;

3. Active hepatitis B or hepatitis C infection;

4. Recent or current use of glucocorticoid or other immunosuppressor;

5. With severe cardiac, liver, renal insufficiency, diabetes and other diseases;

6. Transaminase >2.5ULN, Bilirubin >3ULN,Creatinine>1.25ULN

7. Participate in other clinical research in the past three months; previously treatment with any gene therapy products;

8. Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results;

Related Conditions & MeSH terms

• B Cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell

Intervention

Drug:
• Cyclophosphamide
patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
• Fludarabine
Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).

Biological:
• CART-19
CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Henan Cancer Hospital	The Beijing Pregene Science and Technology Company, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety as assessed by the occurence of study related adverse events	monitor the occurence of study related adverse events	6 months
Secondary	efficacy assessed by anti-tumor activity of CART-19 cells	anti-tumor activity of CART-19 cells will be determined in a follow-on study	2 years
Secondary	duration of CART-19	Determine duration of in vivo survival of CART-19 cells	2 years